Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Pharnext is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Pharnext has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Pharnext. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Pharnext's earnings available for a low price, and how does
this compare to other companies in the same industry?
Pharnext has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
Take a look at our analysis of P0X’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Pharnext's regulatory filings and announcements.
Pharnext is not considered high growth as it is expected to be loss making for the next 1-3 years.
Pharnext's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Pharnext's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. Daniel E. Cohen, MD, PhD is President and Chief Executive Officer of MEDIKHMER PHARMACEUTICAL CO., LTD, is the pioneer of modern genetics and author of the first map of the human genome. He Co-Founded Millennium Pharmaceuticals, Inc., and Pharnext SAS. Mr. Cohen serves as Chief Executive Officer Pharnext SAS. He founded Modern Genetics, Genomics and Pharmacogenomics. He served as the Chief Scientific Officer of Serono Genetics Institute S.A. He joined Serono Genetics Institute S.A. in 1996 as Chief Genomics Officer and Director Général. He served as Vice President of Worldwide Genetics at Serono. He served as a Scientific Advisor for another genomics company. He established the most advanced physical map of the human genome in 1996, at the Foundation Jean Dausset, CEPH, where he worked as Scientific Director, which he co-founded. He serves as President of the Scientific Advisory Board at Molecular Engines Laboratories S.A. He served as the Chairman of Scientific Advisory Board of Moleac Pte Ltd. He serves as a Member of Scientific Advisory Board at Molecular Engines Laboratories S.A. He served as a Director at Serono Genetics Institute S.A. Mr. Cohen is a Professor of Medical Genetics at the University of Paris II. He has authored more than 100 scientific publications, 20 pharmaceutical patents and author of the first maps of the human genome and responsible for many discoveries in medical genetics. He is cited as an inventor on over 15 patents and the winner of many scientific prizes in France and internationally. He has received UNESCO's Prize of New Human Rights, the Daniel Bauperthuy Prize from the French Academy of Sciences for epidemiology and the Grand Prize for Medical Literature for the book, The Genes of Hope, which has been translated into seven languages. Mr. Cohen served as Chairman of Pharnext SAS. He received the Knight of the Legion of Honour (France) in 1998 and the American Academy of Achievement's Golden Plate Award in 1999. Mr. Cohen is a recognized world leader in the field of genomics. He is a Doctor Honoris Causa of Shanghai, Xi'an and Ben Gourion University. He has an M.D. and a Ph.D. in Immunology and Immunogenetics from the University of Paris VII.
Daniel's compensation has been consistent with company performance over the past year.
Daniel's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Pharnext management team is less than 2 years, this suggests a new team.
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapeutics for severe orphan and common neurodegenerative diseases in France. The company’s lead products include PXT3003 that is in Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer’s disease, as well as Parkinson’s disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big data genomics and artificial intelligence platform; and identifies and develops PLEODRUG, a combination of drugs. The company was founded in 2007 and is based in Issy-Les-Moulineaux, France.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.